Indeed, complex tumor microenvironmental products appear to act either locally, at the tumor site, or systemically (through the bloodstream and/or bone marrow) to trigger two main monocyte profiles: (1) metabolic impairment, which leads to differentiation and functional biases that favor the tumor growth and (2) IFN enrichment, suggestive of patient protection. This evidence concerns the gene IFNA1 and neoplasm.